SANDOMIGRAN (pizotifen malate)

Size: px
Start display at page:

Download "SANDOMIGRAN (pizotifen malate)"

Transcription

1 SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants. The malate salt is a white to yellow-tinged crystalline powder. MW = , pka 6.95 in water. Excipients: silica colloidal anhydrous, lactose, magnesium stearate, starch-maize, talcpurified, povidone, acacia, sucrose, titanium dioxide, cetyl palmitate. PHARMACOLOGY Pharmacodynamics Sandomigran (pizotifen) is a competitive serotonin antagonist. It also possesses antihistamine, antibradykinin and weak anticholinergic properties. It is suitable for the prophylactic treatment of migraine, reducing the frequency of attacks, but is without effect in the migraine attack. The migraine attack is thought to consist of a prodromal phase of constriction followed by dilatation of the extracranial vessels. The mode of action of pizotifen in preventing migraine is not fully understood but it is known to inhibit the reuptake of serotonin by blood platelets, preventing loss of tone of extracranial vessels. It also possesses appetite-stimulating and antidepressant properties. Pharmacokinetics The absorption of pizotifen is rapid (absorption half-life hours) and nearly complete (estimated 80%). Peak plasma levels are achieved 4-6 hours following a single oral dose. Metabolism is extensive and the drug is widely distributed. Volume of distribution is at least 7 litres/kg. Protein binding amounts to 91%. The main metabolite (N-glucuronide) is eliminated 1

2 with a half-life of about 23 hours. Less than 1% of the drug is excreted in the urine unchanged although as much as 55% of a dose has been detected in the urine as metabolites. In patients with kidney insufficiency dosage adjustment may therefore be necessary. INDICATIONS Prophylactic (interval) treatment of vascular headaches. - typical and atypical migraine - vasomotor headache - cluster headache (Horton's syndrome) Sandomigran is without effect in the migraine attack. For this purpose preparations containing ergotamine are recommended. CONTRAINDICATIONS Hypersensitivity to pizotifen or any of the excipients in the formulation. PRECAUTIONS Renal impairment Caution is required in patients with renal impairment. Dosage adjustment may be necessary. Hepatic impairment Caution is required in patients with hepatic impairment. Dosage adjustment may be necessary. Hepatic injury has been reported, ranging from transaminase elevations to severe hepatitis. Pizotifen treatment should be discontinued if there is any clinical evidence of hepatic dysfunction during treatment and until the cause of the liver abnormality is determined. Withdrawal symptoms Withdrawal symptoms like depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decreased have been reported following abrupt cessation of pizotifen (see ADVERSE REACTIONS), therefore gradual withdrawal is recommended. Effects on the ability to drive and use machines: Patients should be warned that Sandomigran may cause sedation, somnolence and dizziness. Therefore, caution should be exercised when driving or using machines. 2

3 Patients being treated with Sandomigran and presenting with sedation and/or somnolence episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk. Anticholinergic effects: In view of the very slight anticholinergic effect of pizotifen, caution is required in patients with narrow angle glaucoma (except those successfully treated by surgery) or urinary retention (e.g. prostatic enlargement). Up to now no untoward reactions have been reported in such patients given the recommended dosage. Use in Pregnancy (Category B1) No embryotoxic or teratogenic effects were observed in animal studies and fertility was unimpaired. Clinical data with pizotifen in pregnancy are very limited; it should be administered in pregnancy only if the expected benefits outweigh any potential risks. Use in Lactation Animal studies show that pizotifen enters the milk. Although the concentrations of pizotifen measured in the milk of treated mothers are not likely to affect the infant, its use in nursing mothers is not recommended. Use in Children Experience in children is still limited. Interactions with other medicines The following drugs may exhibit drug interactions with pizotifen upon concomitant administration. Anticipated drug interactions to be considered Pizotifen is extensively metabolized in the liver, primarily by N-glucuronidation. Increased plasma concentration of pizotifen upon concomitant administration of drugs which exclusively undergo glucuronidation can not be excluded. Central nervous system agents: Central effects of sedatives, hypnotics, antihistamines, including certain common cold preparations, and alcohol may be enhanced. Monoamine oxidase inhibitors: MAOIs can prolong and intensify the anticholinergic effects of antihistaminic substances. Concomitant use with MAOIs should therefore be avoided. Cisapride: Concomitant administration of pizotifen with cisapride may lead to reduced efficacy of cisapride. 3

4 Epilepsy Seizures as undesirable effects have been observed more frequently in patients with epilepsy. Pizotifen should be used with caution in patients with epilepsy. Sandomigran coated tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption should not take Sandomigran. ADVERSE REACTIONS The most common reactions are appetite-stimulating effect, increase in body weight and sedation (including somnolence and fatigue). It can usually be avoided by increasing the dosage gradually or reversed by a progressive reduction in dosage. The appetite-stimulating effect of pizotifen may lead to an increase in body weight. The following adverse reactions are ranked under headings of frequency; the most frequent first, using the following convention: Very common ( 1/10); common ( 1/100, < 1/10); uncommon ( 1/1000, < 1/100); rare ( 1/10,000, < 1/1000); very rare (< 1/10,000), including isolated reports. Immune system disorders Hypersensitivity reactions, face oedema Metabolism and nutrition disorders Very common: Increased appetite and body weight increased Psychiatric disorders Depression, CNS stimulation (e.g. aggression, agitation), hallucination, insomnia, anxiety Nervous system disorders Common: Sedation (including somnolence), dizziness Paraesthesia Very rare: Seizures Gastrointestinal disorders Common: Nausea, dry mouth Uncommon Constipation Skin and subcutaneous tissue disorders Urticaria, rash Musculoskeletal and connective tissue disorders Myalgia General disorders and administration site conditions Common Fatigue 4

5 Headache, hypotension and impotence have also been reported during treatment with Sandomigran, but a causal relationship was not established. Adverse drug reactions from post-marketing spontaneous reports The following additional adverse drug reactions have been identified with pizotifen based on post-marketing spontaneous reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency. Hepatobiliary disorders Unknown: Hepatic enzyme increased, jaundice, hepatitis Musculoskeletal and connective tissue disorders Unknown: Muscle cramps Withdrawal symptoms Withdrawal reactions have been reported following abrupt cessation of pizotifen, therefore gradual withdrawal is recommended (see PRECAUTIONS). Withdrawal symptoms may include: depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decreased. DOSAGE AND ADMINISTRATION The dosage should be progressively increased, starting with 0.5 mg daily. The average maintenance dosage is 1.5 mg daily in single or divided doses. Recent studies have shown a single daily dose of 3 tablets (1.5 mg) taken at night to be effective. In refractory cases the dosage may be gradually raised to mg daily in two or three divided doses. OVERDOSAGE Symptoms Symptoms which may be expected are: drowsiness, nausea, dry mouth, tachycardia, pyrexia, hypotension, dizziness, excitatory states (in children), respiratory depression, convulsions (particularly in children), coma. Treatment Treatment is gastric lavage followed by administration of activated charcoal. If necessary, symptomatic treatment should be given including monitoring of the cardiovascular and respiratory symptoms; for excitatory states or convulsions: benzodiazepines. 5

6 PRESENTATION Tablets containing 0.5 mg pizotifen present as mg pizotifen malate (off-white, sugar-coated); 100's. Store below 30 C. Protect from light. SPONSOR NOVARTIS Pharmaceuticals Australia Pty. Ltd. ABN Waterloo Road, NORTH RYDE, NSW 2113 Approved by the Therapeutic Goods Administration: Date of most recent amendment: 5 May

NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.

NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face. 1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM

More information

Cetirizine Proposed Core Safety Profile

Cetirizine Proposed Core Safety Profile Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function

More information

SANDOMIGRAN. 0.5mg tablet Pizotifen malate

SANDOMIGRAN. 0.5mg tablet Pizotifen malate SANDOMIGRAN 0.5mg tablet Pizotifen malate What is in this leaflet This leaflet answers some common questions about Sandomigran. It does not contain all the available information. It does not take the place

More information

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR: M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR: Core Safety Profile Active substance: Flunarizine Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg P RMS: ES/H/PSUR/0013/001 Date of FAR: 13.12.2010 4.3 Contraindications Flunarizine is

More information

European PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam

European PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR: Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated

More information

PRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets

PRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets

More information

Sanomigran 500 microgram Tablets and Sanomigran 1.5 mg Tablets

Sanomigran 500 microgram Tablets and Sanomigran 1.5 mg Tablets Sanomigran 500 microgram Tablets and Sanomigran 1.5 mg Tablets Pizotifen (as malate) Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it

More information

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET 1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full

More information

PRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate

PRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate NORGESIC Orphenadrine citrate and paracetamol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: CAS number: 4682-36-4 Chemical structure: Orphenadrine citrate (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine

More information

PRODUCT INFORMATION. AKINETON (biperiden hydrochloride 2 mg tablets)

PRODUCT INFORMATION. AKINETON (biperiden hydrochloride 2 mg tablets) PRODUCT INFORMATION AKINETON (biperiden hydrochloride 2 mg tablets) NAME OF THE MEDICINE Non-proprietary name: biperiden hydrochloride Structural formula (biperiden): Chemical name (biperiden): α-5-norbornen-2-yl-α-phenyl-1-piperidine

More information

PRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.

PRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes. PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine

More information

Body weight more than 30kg : 10ml (10mg) of the syrup once daily.

Body weight more than 30kg : 10ml (10mg) of the syrup once daily. 1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose

More information

3 PHARMACEUTICAL FORM Coated tablet Round, white to off-white, sugar coated tablets, plain on both sides.

3 PHARMACEUTICAL FORM Coated tablet Round, white to off-white, sugar coated tablets, plain on both sides. SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mebeverine hydrochloride 135 mg coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains 135 mg of mebeverine

More information

P-RMS: FR/H/PSUR/0036/001

P-RMS: FR/H/PSUR/0036/001 Core Safety Profile Active substance: Alprazolam Pharmaceutical form(s)/strength: Tablet uncoated, sugar coated, film coated, 0.25mg Tablet uncoated, 0.4 mg Tablet uncoated, sugar coated, film coated,

More information

PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets

PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets NAME OF THE MEDICINE Active Ingredients: Paracetamol and Codeine Phosphate Paracetamol: Molecular Formula: C 8 H

More information

SIBELIUM Capsules Janssen

SIBELIUM Capsules Janssen SIBELIUM Capsules Janssen NAME OF THE MEDICINAL PRODUCT Trade name SIBELIUM International Non-Proprietary Name (Modified) (rinnm) flunarizine hydrochloride QUALITATIVE AND QUANTITATIVE COMPOSITION Each

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).

More information

Data Sheet. BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other.

Data Sheet. BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other. BICALOX Data Sheet Bicalutamide 50 mg tablets Presentation BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other. Uses Actions

More information

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fexofenadine hydrochloride 180 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 180mg

More information

Migraleve, Migraleve Pink and Migraleve Yellow Product Information

Migraleve, Migraleve Pink and Migraleve Yellow Product Information Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also

More information

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Unichem Allergy Relief Antihistamine Tablets Moss Pharmacy Allergy Relief Antihistamine Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

M0BCore Safety Profile

M0BCore Safety Profile M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze

More information

NEW ZEALAND DATASHEET

NEW ZEALAND DATASHEET NEW ZEALAND DATASHEET COLDREX HOT REMEDY COLD & FLU HOT LEMON Powder for Oral Solution Paracetamol (BP) 1000mg/sachet Presentation Pale yellow, free flowing heterogeneous powder with and odour of lemon

More information

SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS

SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive

More information

PANADOL SINUS DAY & NIGHT TABLETS PRODUCT INFORMATION

PANADOL SINUS DAY & NIGHT TABLETS PRODUCT INFORMATION Product description PANADOL SINUS DAY tablet is a white, film-coated capsule-shaped tablet with flat edges, front and back faces marked with DAY. PANADOL SINUS NIGHT tablet is a white, film-coated round

More information

AUSTRALIAN PRODUCT INFORMATION APO-MEBEVERINE. Mebeverine hydrochloride

AUSTRALIAN PRODUCT INFORMATION APO-MEBEVERINE. Mebeverine hydrochloride 1 NAME OF THE MEDICINE Mebeverine hydrochloride AUSTRALIAN PRODUCT INFORMATION APO-MEBEVERINE Mebeverine hydrochloride 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each APO-MEBEVERINE tablet contains mebeverine

More information

SIFROL Composition Properties Indication

SIFROL Composition Properties Indication SIFROL Boehringer Composition 1 tablet contains: 0.125, 0.25 or 1.0 mg, (S)-2- amino-4,5,6,7-tetrahydro-6-propylamino-benzothiazole dihydrochloride monohydrate equivalent to 0.088, 0.18 or 0.7 mg pramipexole

More information

SUMMARY OF PRODUCT CHARACTERISTICS. One film-coated tablet contains 10 mg of cetirizine dihydrochloride.

SUMMARY OF PRODUCT CHARACTERISTICS. One film-coated tablet contains 10 mg of cetirizine dihydrochloride. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizin STADA 10 mg, film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 10 mg of cetirizine

More information

PRODUCT INFORMATION Panadeine EXTRA

PRODUCT INFORMATION Panadeine EXTRA PRODUCT INFORMATION Panadeine EXTRA COMPOSITION Each caplet brand of capsule-shaped tablet contains: Paracetamol 500 mg Codeine phosphate 15 mg and Maize Starch Purified Talc Pregelatinised Maize Starch

More information

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Telfast 120 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 120 mg of fexofenadine hydrochloride,

More information

AUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM

AUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM AUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 1 NAME OF THE MEDICINE Betahistine dihydrochloride. 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM

More information

NARAMIG QUALITATIVE AND QUANTITATIVE COMPOSITION

NARAMIG QUALITATIVE AND QUANTITATIVE COMPOSITION NARAMIG Naratriptan QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets containing 2.5 mg of naratriptan as naratriptan hydrochloride. PHARMACEUTICAL FORM Film coated tablets. CLINICAL PARTICULARS Indications

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine

More information

PANADOL COLD & FLU MAX HOT LEMON Powder for Oral Solution DATA SHEET

PANADOL COLD & FLU MAX HOT LEMON Powder for Oral Solution DATA SHEET PANADOL COLD & FLU MAX HOT LEMON Powder for Oral Solution Paracetamol (BP) 1000mg/sachet DATA SHEET Presentation Pale yellow, free flowing heterogeneous powder with and odour of lemon Indications Fast,

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizin Mylan 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg of cetirizine

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE MEDICINAL PRODUCT Mebeverine Tablets BP 135 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 135 mg of Mebeverine Hydrochloride

More information

AVIOMARIN 50 mg tablets

AVIOMARIN 50 mg tablets PACKAGE LEAFLET: INFORMATION FOR THE USER AVIOMARIN 50 mg tablets DIMENHYDRINATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacidipine 2 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg lacidipine. Excipient with known

More information

Panadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION

Panadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION Panadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION DESCRIPTION Active Ingredients Paracetamol 500 mg Codeine Phosphate 8 mg Excipients Tablets - Starch - maize, talc - purified, stearic

More information

PRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets

PRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets PRODUCT INFORMATION Sudafed* Sinus Day + Night Relief Tablets Product description Sudafed* Sinus Day + Night Relief tablets contain two separate formulations: day tablets and night tablets. Each Sudafed*

More information

PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP

PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT YOCON-GLENWOOD Tablets 5 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains 5 mg yohimbine hydrochloride. For a full list of excipients, see section 6.1. 3

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizine 10 mg Film-Coated Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg cetirizine dihydrochloride.

More information

Levocetirizine dihydrochloride

Levocetirizine dihydrochloride INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate

More information

PRODUCT INFORMATION PANADOL COLD & FLU MAX HOT LEMON POWDER NAME OF THE MEDICINE. Chemical structure: CAS 2 Registry Number: DESCRIPTION

PRODUCT INFORMATION PANADOL COLD & FLU MAX HOT LEMON POWDER NAME OF THE MEDICINE. Chemical structure: CAS 2 Registry Number: DESCRIPTION PRODUCT INFORMATION PANADOL COLD & FLU MAX HOT LEMON POWDER NAME OF THE MEDICINE Active ingredient: Paracetamol Chemical structure: CAS 2 Registry Number: 103-90-2 DESCRIPTION Paracetamol is a white, crystalline

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU

More information

Emergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.

Emergency contraception is an occasional method. It should in no instance replace a regular contraceptive method. 1. NAME OF THE MEDICINAL PRODUCT: Levonorgestrel Tablets 1.5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each tablet contains levonorgestrel 1.5 mg. Excipient with known effect: Each tablet contains

More information

Package Information Leaflet: Information for the user. Calmaben Coated Tablets

Package Information Leaflet: Information for the user. Calmaben Coated Tablets Package Information Leaflet: Information for the user Calmaben Coated Tablets Active substance: diphenhydramine hydrochloride Read all of this leaflet carefully before you start taking this medicine because

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablet 5 mg cetirizine / 120 mg pseudoephedrine. Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablet 5 mg cetirizine / 120 mg pseudoephedrine. Date of FAR: Core Safety Profile Active substance: Cetirizine + Pseudoephedrine Pharmaceutical form(s)/strength: Prolonged release tablet 5 mg cetirizine / 120 mg pseudoephedrine P - RMS: BE/H/PSUR/0019/001 Date of

More information

VALERIANA OFFICINALIS 445 MG COATED TABLET Summary of Product Characteristics

VALERIANA OFFICINALIS 445 MG COATED TABLET Summary of Product Characteristics Sandoz Business use only Page 1 of 5 Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Valeriaan Sandoz omhulde tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains

More information

Ospolot Sulthiame 50mg and 200mg Tablets

Ospolot Sulthiame 50mg and 200mg Tablets NAME OF THE MEDICINE Sulthiame Sulthiame 50mg and 200mg Tablets Chemical name: 4-(Tetrahydro-2H-1,2-thiazin-2-yl)benzenesulfonamide- S,S-dioxide The molecular weight of the compound is 290.4 and the CAS

More information

TRAPADOL INJECTION FOR I.V./I.M. USE ONLY

TRAPADOL INJECTION FOR I.V./I.M. USE ONLY TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally

More information

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013 CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment

More information

SIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.

SIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product. SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride

More information

PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other.

PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other. Product description PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other. Ingredients Active Ingredients: Paracetamol

More information

PRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets

PRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets PRODUCT INFORMATION Sudafed* Sinus Day + Night Relief Tablets Name of the Medicine Paracetamol CAS 2 Registry Number: 103-90-2 Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 Triprolidine

More information

Lorazepam Tablets, USP

Lorazepam Tablets, USP Lorazepam Tablets, USP DESCRIPTION: Lorazepam, an antianxiety agent, has the chemical formula, 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H -1,4-benzodiazepin-2-one: Cl H N N O Cl OH It is a white

More information

EU Core Safety Profile

EU Core Safety Profile EU Core Safety Profile Active Substance: Triazolam Brand Names: HALCION, SOMESE Pharmaceutical form(s)/strength: Tablets RMS: Finland Date: 9 th Dec 2013 Supersedes: 24 th May 2010 4.3. Contraindications

More information

M0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR:

M0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR: M0BCore Safety Profile Active substance: Zolmitriptan Pharmaceutical form(s)/strength: ordispersible tablet P-RMS: SE/H/PSUR/0022/002 Date of FAR: 15.03.2014 4.3 Contraindications Zolmitriptan is contraindicated

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 100 mg of trimethoprim. For the full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 100 mg of trimethoprim. For the full list of excipients, see section 6.1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Trimethoprim 100 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 100 mg of trimethoprim. For the full list

More information

Package leaflet: Information for the user Zirtek Allergy Relief 10 mg film-coated tablets Cetirizine dihydrochloride

Package leaflet: Information for the user Zirtek Allergy Relief 10 mg film-coated tablets Cetirizine dihydrochloride Package leaflet: Information for the user Zirtek Allergy Relief 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR: 0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration

More information

APPROPRIATE USE GUIDE

APPROPRIATE USE GUIDE APPROPRIATE USE GUIDE PRILIGY is indicated for the treatment of premature ejaculation in adult men aged 18 to 64 years 1 * PRILIGY should only be prescribed to patients who meet all the following criteria:

More information

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: 0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET NEW ZEALAND DATA SHEET VERGO 16 1. Product Name Vergo 16, 16 mg, tablet. 2. Qualitative and Quantitative Composition Each tablet contains 16 mg of betahistine dihydrochloride. For the full list of excipients,

More information

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Package leaflet: Information for the user Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Otrivin Menthol (without preservative) 1.0 mg/ml nasal spray, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 1.0 mg

More information

Information leaflet for primary care: Agomelatine

Information leaflet for primary care: Agomelatine Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin

More information

MARKETING AUTHORISATION NO. 403/2007/01-02 Annex 2 Summary of Product Characteristics

MARKETING AUTHORISATION NO. 403/2007/01-02 Annex 2 Summary of Product Characteristics Pyrazinamide 500mg tablets ( Antibiotice S. A. ), TB267 WHOPAR part 4 supplier s translation of the text as approved by the stringent regulatory authority June 2014 MARKETING AUTHORISATION NO. 403/2007/01-02

More information

New Zealand Datasheet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Bicalutamide 50 mg film coated tablets

New Zealand Datasheet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Bicalutamide 50 mg film coated tablets New Zealand Datasheet 1 PRODUCT NAME Binarex 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Bicalutamide 50 mg film coated tablets 3 PHARMACEUTICAL FORM Binarex tablets are white to off-white, circular, biconvex,

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Desmopressin acetate 0.2 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.2 mg desmopressin acetate tablet corresponds to

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklonova 500 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tranexamic acid 500 mg. For the full list of excipients,

More information

PRODUCT INFORMATION. Sudafed* Sinus + Allergy & Pain Relief Tablets

PRODUCT INFORMATION. Sudafed* Sinus + Allergy & Pain Relief Tablets PRODUCT INFORMATION Sudafed* Sinus + Allergy & Pain Relief Tablets Name of the Medicine Paracetamol CAS 2 Registry Number: 103-90-2 Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 Triprolidine

More information

PARACOD Tablets (Paracetamol + Codeine phosphate)

PARACOD Tablets (Paracetamol + Codeine phosphate) Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s

More information

Molecular formula: Molecular weight: C 8 H 9 NO 2 CAS Registry no.:

Molecular formula: Molecular weight: C 8 H 9 NO 2 CAS Registry no.: Parapane Paracetamol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: Paracetamol N-(4-hydroxyphenyl) Structural formula: Molecular formula: 151.20 Molecular weight: C 8 H 9 NO

More information

New Zealand Data Sheet

New Zealand Data Sheet New Zealand Data Sheet 1. PRODUCT NAME Ox-Pam 10mg Tablet Ox-Pam 15mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ox-Pam 10mg tablet contains 10mg oxazepam Ox-Pam 15mg tablet contains 15mg oxazepam

More information

New Zealand Data Sheet

New Zealand Data Sheet Arrow - Sumatriptan Sumatriptan Injection 6mg/0.5mL Presentation New Zealand Data Sheet ARROW SUMATRIPTAN Injection 6mg/0.5mL is a clear, colourless to pale yellow solution in a prefilled syringe. Uses

More information

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY robaxin / robaxin -7 50 (methocarbamol tablets, USP) Rx Only DESCRIPT ION robaxin /robaxin -750 (methocarbamol tablets, USP), a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant

More information

IMIGRAN. Sumatriptan Tablets. Tablets containing 50mg or 100 mg of sumatriptan base as the succinate salt.

IMIGRAN. Sumatriptan Tablets. Tablets containing 50mg or 100 mg of sumatriptan base as the succinate salt. IMIGRAN Sumatriptan Tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets containing 50mg or 100 mg of sumatriptan base as the succinate salt. PHARMACEUTICAL FORM IMIGRAN tablets 50 mg are pink, film-coated,

More information

Translated from Latvian Approved by SAM on

Translated from Latvian Approved by SAM on Translated from Latvian SAM on 29.07.2010 1. NAME OF THE MEDICINAL PRODUCT FENKAROL 10 mg Tablets FENKAROL 25 mg Tablets FENKAROL 50 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance

More information

Package Leaflet: Information for the user. Anti-Hist Allergy 10mg Film-Coated Tablets. Cetirizine dihydrochloride

Package Leaflet: Information for the user. Anti-Hist Allergy 10mg Film-Coated Tablets. Cetirizine dihydrochloride Package Leaflet: Information for the user Anti-Hist Allergy 10mg Film-Coated Tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains

More information

NEW ZEALAND DATA SHEET. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg cetirizine hydrochloride.

NEW ZEALAND DATA SHEET. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg cetirizine hydrochloride. NEW ZEALAND DATA SHEET 1. PRODUCT NAME Zista, 10 mg, tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg cetirizine hydrochloride. Excipient with known effect: lactose monohydrate

More information

Stilnoct 10mg Tablets: White to off-white film-coated oblong tablet, scored and engraved SN 10 on one side, containing 10mg zolpidem tartrate.

Stilnoct 10mg Tablets: White to off-white film-coated oblong tablet, scored and engraved SN 10 on one side, containing 10mg zolpidem tartrate. 1. NAME OF THE MEDICINAL PRODUCT Stilnoct 5mg Stilnoct 10mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Stilnoct 5mg Tablets: Round white film coated tablets containing 5mg zolpidem tartrate. Stilnoct

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1. Name of the Medicinal Product Sumatriptan Merck 50 mg film-coated tablet Sumatriptan Merck 100 mg film-coated tablet 2. Qualitative and Quantitative Composition Each

More information

NAME OF THE MEDICINAL PRODUCT IMODIUM CAPS. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mg loperamide hydrochloride (HCl) per capsule.

NAME OF THE MEDICINAL PRODUCT IMODIUM CAPS. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mg loperamide hydrochloride (HCl) per capsule. NAME OF THE MEDICINAL PRODUCT IMODIUM CAPS QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mg loperamide hydrochloride (HCl) per capsule. PHARMACEUTICAL FORM AND DESCRIPTION Capsules, hard White powder filled

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Atrosan Devil's Claw film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 480 mg of extract

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklo-f 500 mg film coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains tranexamic acid 500 mg For the full

More information

SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM. I.N.N. : Rilmenidine

SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM. I.N.N. : Rilmenidine SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM I.N.N. : Rilmenidine 1. DENOMINATION HYPERIUM 1 mg, tablets 2. COMPOSITION Rilmenidine (I.N.N.) dihydrogenphosphate.1.544 mg amount equivalent to rilmenidine

More information

(RS)-2-[2-[4-[(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic acid hydrochloride.

(RS)-2-[2-[4-[(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic acid hydrochloride. Alzene Cetirizine hydrochloride PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: cetirizine hydrochloride. (RS)-2-[2-[4-[(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT ALVERINE Mayoly Spindler, 60 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 60 mg of alverine citrate.

More information